121 related articles for article (PubMed ID: 26095782)
1. PD-L1 expression by circulating breast cancer cells.
David R
Lancet Oncol; 2015 Jul; 16(7):e321. PubMed ID: 26095782
[No Abstract] [Full Text] [Related]
2. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Schalper KA; Velcheti V; Carvajal D; Wimberly H; Brown J; Pusztai L; Rimm DL
Clin Cancer Res; 2014 May; 20(10):2773-82. PubMed ID: 24647569
[TBL] [Abstract][Full Text] [Related]
3. By the numbers: does circulating tumor cell enumeration have a role in metastatic breast cancer?
Liu MC
J Clin Oncol; 2014 Nov; 32(31):3479-82. PubMed ID: 25245442
[No Abstract] [Full Text] [Related]
4. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS
Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction.
Abiko K; Mandai M; Hamanishi J; Yoshioka Y; Matsumura N; Baba T; Yamaguchi K; Murakami R; Yamamoto A; Kharma B; Kosaka K; Konishi I
Clin Cancer Res; 2013 Mar; 19(6):1363-74. PubMed ID: 23340297
[TBL] [Abstract][Full Text] [Related]
6. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy.
Wang HY; Ahn S; Kim S; Park S; Park S; Han H; Sohn JH; Kim S; Lee H
Exp Mol Pathol; 2014 Dec; 97(3):445-52. PubMed ID: 25217799
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K
In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230
[TBL] [Abstract][Full Text] [Related]
8. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
[TBL] [Abstract][Full Text] [Related]
9. CTC immune escape mediated by PD-L1.
Wang X; Sun Q; Liu Q; Wang C; Yao R; Wang Y
Med Hypotheses; 2016 Aug; 93():138-9. PubMed ID: 27372873
[TBL] [Abstract][Full Text] [Related]
10. TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells.
Boes M; Meyer-Wentrup F
Cancer Lett; 2015 May; 361(1):49-56. PubMed ID: 25697485
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer.
Mostert B; Sleijfer S; Foekens JA; Gratama JW
Cancer Treat Rev; 2009 Aug; 35(5):463-74. PubMed ID: 19410375
[TBL] [Abstract][Full Text] [Related]
13. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients.
Soria JC; Gauthier LR; Raymond E; Granotier C; Morat L; Armand JP; Boussin FD; Sabatier L
Clin Cancer Res; 1999 May; 5(5):971-5. PubMed ID: 10353728
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells and emerging blood biomarkers in breast cancer.
Criscitiello C; Sotiriou C; Ignatiadis M
Curr Opin Oncol; 2010 Nov; 22(6):552-8. PubMed ID: 20706122
[TBL] [Abstract][Full Text] [Related]
15. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
16. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
[TBL] [Abstract][Full Text] [Related]
17. [Locally advanced breast cancer (methods of treatment)].
Portnoĭ SM
Vopr Onkol; 2011; 57(5):553-8. PubMed ID: 22238923
[No Abstract] [Full Text] [Related]
18. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features.
Skondra M; Gkioka E; Kostakis ID; Pissimissis N; Lembessis P; Pectasides D; Koutsilieris M
Anticancer Res; 2014 Nov; 34(11):6691-9. PubMed ID: 25368276
[TBL] [Abstract][Full Text] [Related]
20. A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer.
Wang J; Cao MG; You CZ; Wang CL; Liu SL; Kai C; Dou J
Cell Mol Biol (Noisy-le-grand); 2012 Feb; 58 Suppl():OL1641-5. PubMed ID: 22340707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
